U.S. Metals and Mining Stock News

We feel now is a pretty good time to analyse QuickLogic Corporation's ( NASDAQ:QUIK ) business as it appears the...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Some Whitehawk Therapeutics, Inc. ( NASDAQ:WHWK ) shareholders may be a little concerned to see that the President...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

In recent days, Everpure, Inc. (formerly Pure Storage) has rebranded, prepared a ticker change to “P,” and reported quarterly revenue of US$1.06 billion and earnings per share of US$0.69, both ahead of consensus estimates, while attracting heightened attention as one of the most oversold data center names. At the same time, analysts have turned increasingly positive, citing rapid bookings growth, strong win rates in AI-focused storage deals, and Everpure’s ambition to become an intelligent,...

Institutional interest sets the stage for Kaiser Aluminum Recent filings show large investors increasing exposure to Kaiser Aluminum (KALU), with hedge funds and institutions holding nearly all available shares. For you, that concentration raises questions about liquidity, expectations, and potential volatility. See our latest analysis for Kaiser Aluminum. Kaiser Aluminum’s recent 7 day share price return of 8.4% and 30 day return of 11.85% at a share price of $142.67, together with a very...

Recent estimate revisions for 2026, which are slightly higher on balance, together with a reported 15.2% dividend yield, have pushed Innovative Industrial Properties (IIPR) onto more investors’ radar as cannabis operators continue to face industry pressures. See our latest analysis for Innovative Industrial Properties. The latest share price of US$51.0 leaves investors weighing mixed signals, with a 1-year total shareholder return of 19.57% contrasting with a 5-year total shareholder return...

Recent leadership changes at Skyward Specialty Insurance Group (SKWD), including the retirement of a long-serving director and the nomination of reinsurance veteran Peter Hearn, have sparked fresh questions about the insurer's near term direction. See our latest analysis for Skyward Specialty Insurance Group. Despite the leadership changes and fresh sponsorship and earnings headlines, the stock’s momentum has cooled, with a 1 year total shareholder return of a 13.25% decline contrasting with...

In early April 2026, American Electric Power Company received detailed feedback from the Federal Energy Regulatory Commission on safety-driven design and drilling plans for its Elkhart and Twin Branch hydroelectric spillway stabilization projects, including requirements for final design reports, emergency action planning, and drilling risk mitigation measures. This level of regulatory engagement highlights how AEP’s infrastructure reliability and dam safety work runs alongside its...

Amphenol (APH) is back in focus after its IT datacom segment benefited from elevated hyperscaler AI data center spending and its role as a key connector supplier to leading chipmakers such as Nvidia. See our latest analysis for Amphenol. The recent AI data center momentum and acquisitions like CommScope's CCS appear to be reflected in Amphenol's recent 7 day share price return of 9.96%, while its 1 year total shareholder return of 116.74% and 5 year total shareholder return of 330.35% point...

In early April 2026, Teledyne Technologies announced extensive support for NASA’s Artemis II mission, supplying mission-critical hardware, communications, power-protection, and imaging systems spanning the Space Launch System rocket, Orion spacecraft, and global tracking infrastructure. These Artemis II contributions, together with new autonomy software at Teledyne FLIR and wins in marine and space imaging, underscore how deeply Teledyne’s high-reliability technologies are embedded across...

With no single headline event driving attention, Mission Produce (AVO) is on investors’ radars after recent share performance and underlying business metrics began to attract closer scrutiny of its avocado focused model. See our latest analysis for Mission Produce. At a share price of $14.81, Mission Produce has seen a 30 day share price return of 11.19% and a 90 day share price return of 21.29%. The 1 year total shareholder return of 48.69% contrasts with a weaker 5 year total shareholder...

Bloom Energy (BE) is back in the spotlight after securing a supply agreement with American Electric Power for up to 1 gigawatt of fuel cells to support AI-driven data centers. See our latest analysis for Bloom Energy. Bloom Energy’s share price has surged over the past year, with a year to date share price return of 68.91% and a very large 1 year total shareholder return. This reflects how the AEP deal, strong recent results, ambitious guidance, and a new CFO have reset expectations around...

In recent days, Getty Realty received an upgrade to a Zacks Rank #2 (Buy) after analysts raised their earnings estimates, reflecting a more favorable outlook for the net-lease REIT’s performance. This upgrade, underpinned by a modest increase in the Zacks Consensus Estimate, aligns closely with existing expectations for stable cash flows and disciplined balance sheet management. Now we’ll explore how this improved earnings outlook, signaled by the Zacks Rank upgrade, fits into Getty...

Equinix (EQIX) has been upgraded to a Zacks Rank #1. This reflects rising confidence in its earnings outlook ahead of the upcoming Q1 2026 report and is drawing fresh attention to the stock. See our latest analysis for Equinix. At a share price of US$1,030.24, Equinix has posted a 5.84% 30 day share price return and a 34.83% year to date share price return. Its 1 year total shareholder return of 35.70% reflects momentum that recent earnings optimism and the earlier Scotiabank valuation driven...

In recent months, NuScale Power has faced multiple securities‑fraud class action lawsuits and investor concern over its partnership with ENTRA1 Energy, alongside weaker financial results and elevated cash burn, raising questions about its nuclear commercialization path. These legal challenges center on allegations that NuScale misrepresented ENTRA1’s nuclear experience, putting a spotlight on management credibility just as the company seeks to advance its small modular reactor rollout and...

Investors may be wondering if FirstEnergy at around US$51.43 is offering good value right now, or if the recent optimism has already been priced in. The stock has returned 0.2% over the last 7 days, 1.5% over the past month, 13.6% year to date, 31.8% over 1 year, 42.7% over 3 years and 76.7% over 5 years, which puts recent moves into a longer term context. Recent coverage around FirstEnergy has focused on its position in the US utilities sector and how the company fits into portfolios...

Keurig Dr Pepper (KDP) is drawing attention after recent share performance, with the stock near US$26.57 and total return figures showing mixed results over the past year and the past 3 months. See our latest analysis for Keurig Dr Pepper. The recent 7 day share price return of 4.98% contrasts with weaker 30 day and year to date share price returns. However, the 1 year total shareholder return of a 21.90% decline underlines that longer term performance has lagged and recent momentum is only...

Pinterest (PINS) is back in focus after multiple securities class action lawsuits accused the company of misleading investors about tariff related pressure on advertisers, weakening ad revenues, and looming restructuring. See our latest analysis for Pinterest. The legal headlines and restructuring plan come after a sharp reset in expectations, with a 30 day share price return of 9.08% and a 90 day share price return of 35.08%. This comes alongside a 33.18% decline in 1 year total shareholder...

In recent days, YETI Holdings reported first-quarter results that exceeded Wall Street expectations on both revenue and earnings, and management raised its full-year profit outlook while highlighting renewed strength in its higher-margin drinkware category. This combination of better-than-expected performance and upgraded guidance suggests that YETI’s core product mix and cost controls are currently working more effectively than previously appreciated by many investors. We’ll now examine...

In early April 2026, Aehr Test Systems reported Q3 results showing sales of US$10.31 million and a wider quarterly net loss, while also filing for a US$60 million at-the-market follow-on equity offering. Despite weaker recent revenues, the company highlighted record quarterly bookings above US$37 million and a backlog exceeding US$50 million, underscoring strong demand for its AI-focused wafer- and package-level burn-in systems. With the stock recently rising and record AI-related bookings...

Recently, FinVolution Group insider Tiezheng Li acquired a large block of company stock options, signaling his willingness to increase exposure to the business. This move is often read by investors as a meaningful expression of management’s confidence in the company’s direction and long-term prospects. We’ll now examine how Tiezheng Li’s sizeable stock option purchase could shape FinVolution Group’s investment narrative and perceived management conviction. AI is about to change...

Index removal puts Dime Community Bancshares in focus Dime Community Bancshares (DCOM) has been removed from the NASDAQ Composite Index, a change that can affect its visibility, prompt index-tracking funds to rebalance, and help explain recent shifts in its US$1.6b market value. See our latest analysis for Dime Community Bancshares. Despite the index removal, the recent 13.33% 1 month share price return and 20.82% year to date share price return, alongside a 55.40% 1 year total shareholder...

Ascendis Pharma recently reported Phase 2 COACH trial data showing that combining once-weekly TransCon CNP and TransCon hGH improved growth, arm span, spinal canal dimensions, and lower limb alignment in children with achondroplasia over 52 weeks, with all participants completing a full year of therapy. In parallel, the company secured U.S. orphan drug exclusivity for YUVIWEL through February 27, 2033 and began its commercial U.S. launch, potentially strengthening its rare-disease growth...